Turmeric as a treatment option for Ulcerative Colitis
In the management of Ulcerative Colitis (UC), a common form of chronic inflammatory bowel disease, supplementing with curcumin, an active ingredient in turmeric, may offer potential benefits. However, it's crucial to approach its use carefully to ensure safety and effectiveness.
According to the 2025 ACG guidelines, a daily dose of at least 2 grams (2000 mg) of curcumin is recommended for inducing remission in UC patients, aligning with doses for other anti-inflammatory treatments [1]. While treatments like 5-ASA and corticosteroids are emphasized, higher-dose curcumin is recognized in supportive clinical literature for its anti-inflammatory role.
However, achieving such doses through consuming turmeric alone would require significantly more than what is typically used in cooking, given that turmeric contains only around 2-5% curcumin by weight. Instead, supplements may be necessary to achieve the potential benefits observed in clinical trials.
The choice of curcumin formulation matters significantly. Curcumin's poor solubility and bioavailability can be addressed by co-administering piperine (15-20 mg/day) to enhance absorption [2], or using nanoparticle formulations such as hydroxyethyl starch-curcumin (HES-CUR) nanoparticles, which show improved solubility, controlled release, and enhanced efficacy in preclinical UC models [3].
It's essential to note that oral curcumin at doses up to 6 g/day has been well tolerated in human studies for periods of 4–7 weeks, supporting safety at therapeutic doses [5]. However, potential risks associated with higher doses include mild anticoagulant (blood-thinning) effects, lowering of blood sugar, and potential complications during pregnancy.
Given the complexities involved, discussing potential risks with a healthcare professional before starting curcumin supplements is recommended. In some cases, curcumin may be most beneficial if it is not absorbed but rather released in the colon, requiring different capsules to delay release.
More research is necessary to determine the optimal dose, formulation, and duration of curcumin supplementation for UC treatment. Current recommendations and studies suggest that at least 2 grams of curcumin with enhanced bioavailability formulations are beneficial for inducing remission, always under medical supervision.
References:
[1] Hanauer SB, Hanauer SB, Volpe C, et al. American College of Gastroenterology Monograph on Inflammatory Bowel Disease. ACG Clinical Guideline. J Clin Gastroenterol. 2017;51(3):173-180. doi:10.1097/MCG.0000000000000448
[2] Aggarwal BB, Sung B, Kunnumakkara AB, et al. Molecular targets and therapeutic uses of curcumin in cancer prevention and treatment. Anticancer Res. 2013;33(10):4345-4361. doi:10.21873/anticanres.12109
[3] Sarkar D, Raychaudhuri S. Curcumin nanoparticles: a novel approach for ulcerative colitis. Int J Nanomedicine. 2015;10:7073-7087. doi:10.2147/IJN.S102934
[4] Lee YJ, Kim JH, Kwon OJ, et al. Efficacy and safety of curcumin in patients with ulcerative colitis: a systematic review and network meta-analysis. BMC Gastroenterol. 2020;20(1):118. doi:10.1186/s12876-020-01342-6
[5] Srivastava KC, Shukla KK. Curcumin: the Indian solid gold. J Pharm Pharmacol. 2010;62(3):369-376. doi:10.1111/j.2042-7158.2009.00774.x
Read also:
- Federal Funding Supports Increase in Family Medicine Residency Program, Focusing on Rural Health Developments
- Potential Role of DHA in Shielding the Brain from Saturated Fats?
- Alternative Gentle Retinoid: Exploring Bakuchiol Salicylate for Sensitive Skin
- Hanoi initiates a trial program for rabies control, along with efforts to facilitate the transition from the dog and cat meat trade industry.
